Oliver W. Press

Appointments and Affiliations

Fred Hutchinson Cancer Research Center

Clinical Research Division

Member, Appointed: 1996

Fred Hutchinson Cancer Research Center

Lymphoma Research

Penny L. Peterson Endowed Chair, Appointed: 2001

University of Washington Medical Center

Medicine

Professor, Appointed: 1996

Mailing Address

Fred Hutchinson Cancer Research Center

1100 Fairview Avenue N.

P.O. Box 19024

D3-190

Seattle, Washington 98109-1024

United States

Contact

Phone: (206) 667-1864

Fax: (206) 667-1874

press@u.washington.edu

http://labs.fhcrc.org/press/index.html

Degrees

M.D., University of Washington, Medical Scientist Training Program, 1979.

Ph.D., University of Washington, Biological Structure, 1977.

B.S., Stanford University, Biology, 1973.

Research Interests

My program is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma and acute and chronic leukemias. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.

Additional Experience

Postgraduate Training in Internal Medicine:
Fellow in Oncology, University of Washington/Fred Hutchinson Cancer Research Center, 1983-1986
Chief Residency, University of Washington Medical Center, Seattle, 1982-1983
Residency, Massachusetts General Hospital, Boston, 1980-1982
Internship, Massachusetts General Hospital, Boston, 1979-1980

Board Certification:
Medical Oncology Certification (A.B.I.M.), November, 1985
American Board of Internal Medicine, Sept. 15, 1982
National Board of Medical Examiners, July 1, 1980

Licensure:
State of Washington, #20170 (8/6/82).

Editorial Positions:
Associate Editor, Journal of the National Cancer Institute, 1991-1995
Managing Editor, annals of Hematology, 1998-2001
Editor, Blood, 2001-present
Editor, Journal of Therapeutic Immunology, 1995-1999
Editor, Advances in Leukemia/Lymphoma
Editor, Tumor Targeting
Editor, Cancer Biotherapy and Radiopharmaceuticals
Editor, Cytokines, Cellular & Molecular Therapy
Reviewer, Cancer Research/Clinical Cancer Research/Journal of Immunology/Journal of Clinical Oncology/Blood/Chest.

Memberships

American Association for Cancer Research

American Association of Physicians

American Federation for Clinical Research, Councilor for Washington

American Medical Association

American Society for Clinical Investigation

American Society for Clinical Oncology

American Society for Gene Therapy

American Society of Hematology

Southwest Oncology Group

Honors and Awards

2009, Co-Chair, Lymphoma Steering Committee, National Cancer Institute

2007, Ellen Glesby Cohen Leadership Award, Lymphoma Research Foundation

2005, Chairman, Scientific Advisory Board, Lymphoma Research Foundation

2002, Selected as one of Seattle's 'Best Doctors', Seattle Magazine

2001-2003, Selected as one of 'America's Top Doctors',

2000, Election to the American Association of Physicians ('Old Turks'),

1998, CRS-Cygnus Award for Outstanding Work in Drug Delivery,

1996, Election to the American Society for Clinical Investigation ('Young Turks'),

1993-1995, Recipient of the first Boeing Corporate Medical Research Award,

1988-1989, Elsa Pardee Award for Cancer Research,

1987-1992, First Independent Research and Training Award from the National Institutes of Health,

1985-1986, Young Investigator Award from the American Society for Clinical Oncology,

1985-1988, Clinical Oncology Career Development Award from the American Cancer Society,

1979, PhD Thesis Honors, University of Washington

1979, Medical Auxiliary MD, PhD Award,

1979, Graduation with 'Highest Honors' from University of Washington School of Medicine,

1979, Robert S. Evans Award,

1979, John J. Bonica Prize in Anesthesiology,

1979, Lamport Biomedical Research Prize,

1979, Seattle Academy of Internal Medicine Prize,

1978, Scholarship from International College of Surgeons,

1976, Alpha Omega Alpha, Honorary Medical Fraternity (elected as 3rd year student in Spring, 1976),

1973, Phi Beta Kappa, Stanford University

1973, Departmental Honors and Departmental Distinction in Biology, Stanford University

1970-1973, George E. Gamble Honors Scholarship, Stanford University

Previous Positions

2005-2009, Clinical Research in Hematology and Hematologic Malignancies, Seattle Cancer Care Alliance

1996-2007, Biological Structure, University of Washington, Biological Structure

1993-2000, Acting Program Director, University of Washington Medical Center, High-Dose Chemotherapy Unit

1991-1996, Associate Member, Fred Hutchinson Cancer Research Center

1991-2006, Associate Director, University of Washington, Medical Scientist Training Program

1991-1996, Associate Professor in Medicine, University of Washington

1991-2006, Associate Director, Medical Scientist Training Program, University of Washington, School of Medicine

1988-1991, Adjunct Assistant Professor of Biological Structure, University of Washington

1987-1991, Assistant Professor in Medicine, University of Washington

1986-1991, Assistant Member, Fred Hutchinson Cancer Research Center

1983-1986, Senior Fellow, Fred Hutchinson Cancer Research Center

1982-1986, Acting Instructor in Medicine, University of Washington

1979-1982, Clinical Fellow in Medicine, Harvard University, Medical School

Funding

Lymphoma Research Foundation: Optimizing Adoptive T Cell Immunotherapy for Mantle Cell Lymphoma, 2007 to 2010.

National Institutes of Health (NIH): CD45 Pretargeted Radioimmunotherapy for AML, 2004 to 2008.

Leukemia and Lymphoma Society of America: Allogeneic Transplantation for Lymphomas and Leukemias Using Reduced Intensity Conditioning Regimens Containing Radiolabeled Anti-CD20 and Anti-CD45 Monoclonal Antibodies, 2002 to 2007.